XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating activities    
Net loss $ (5,340,773) $ (6,109,225)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,669 4,797
Equity-based compensation expense 203,345 313,903
In-process research and development technology 0 1,987,900
Changes in operating assets and liabilities:    
Grants receivable 1,480,490 0
Prepaid expenses and other current assets 280,728 300,342
Accounts payable 627,576 150,302
Accrued expenses and other current liabilities (422,470) (168,845)
Net cash used in operating activities (3,169,435) (3,520,826)
Investing activities    
Purchase in-process research and development technology 0 (1,500,000)
Net cash used in investing activities 0 (1,500,000)
Financing activities    
Proceeds from issuance of equity securities, net 336,682 0
Net cash provided by financing activities 336,682 0
Net decrease in cash, cash equivalents and restricted cash (2,832,753) (5,020,826)
Cash, cash equivalents and restricted cash at beginning of period 12,106,435 29,214,380
Cash, cash equivalents and restricted cash at end of period 9,273,682 24,193,554
Non-cash investing and financing activities:    
Common stock issued for in-process research and development technology 0 487,900
Accrued issuance costs for public offering $ 25,000 $ 0